By the spring of 2012, Bascom Palmer Eye Institute will be one of the first centers in the Southeast to have the newly FDA-approved Catalys Precision Laser System®.Patients in these trials have an implant placed in their eyes that dispenses the test drug, Ciliary neurotrophic factor (CNTF). Two Phase1, FDA-approved clinical trials have been targeted to potentially protect and restore vision for patients with optic nerve diseases, including glaucoma and optic nerve stroke.Multiple gene variants, recently identified via two ongoing clinical trials, may help explain why some patients have elevated eye pressure following use of the drug triamcinolone® for treatment of such conditions as swelling of the retina due to diabetes and retinal vein occlusions.Alfonso, M.D., chairman of Bascom Palmer Eye Institute, “From advanced medical and surgical treatment options to new trends in refractive surgery and oculoplastics, didactical presentations and interactive panel discussions covered the gamut of both remarkable achievements and exciting possibilities within the ever-changing field of ophthalmology.”Ĭurrent clinical trials and research efforts shared at the meeting included: “The tremendous volume of information presented at the Scientific Meeting created a unique collaborative platform, which many of the world's ophthalmologists can now use to explore new ways of approaching patient care and vision research,” said Eduardo C.
With 180 distinguished presenters, topics discussed ranged from research breakthroughs in cataract surgery and gene therapy, to targeted goals of new clinical trials regarding the treatment of glaucoma and optic nerve diseases. Nearly 650 ophthalmologists from around the world attended, including 300 Bascom Palmer alumni.
Bascom Palmer Eye Institute, the nation's No.1 ranked eye hospital and part of UHealth-University of Miami Health System, began its golden anniversary year by hosting a global scientific meeting February 2 - 4 in Miami.
0 kommentar(er)
